Long acting GLP-1 receptor agonist (injectable)
Tg103 sc
TG103_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.44 (0.01 to 29.89) | 0.68 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.46 (0.00 to 35.65) | 0.74 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 23.81 (3.32 to 388) | 0.07 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 13.76 (1.69 to 284) | 0.25 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 7.57 (1.59 to 63.79) | 0.11 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.45 (0.01 to 37.52) | 0.71 |